Literature DB >> 902455

The pharmacokinetics of [3H]-vincristine in man.

R A Bender, M C Castle, D A Margileth, V T Oliverio.   

Abstract

The pharmacokinetics, metabolism, and excretion of aromatically labeled tritiated vincristine (VCR) was examined in 4 patients. Clearance of radioactivity from the blood was triphasic with half-life t1/2 values of 0.85, 7.4, and 164 min. The initial phases probably represent distribution and binding to formed blood elements which exceeded 50% of the administered dose by 20 min. Excretion of radioactivity was principally fecal, with 33% recovered in the feces by 24 hr and 69% by 72 hr. Considerably less radioactivity (12%) was excreted in the urine over the 72-hr period. Approximately 40% of fecally excreted and 46% of urinary excreted radiolabel represented metabolites, which suggests that at least 34% of the VCR dose was excreted as metabolies. Plasma metabolites represented from less than 1% to 30% or more of radioactivity in plasma. Ultraviolet spectral analysis of all metabolites revealed preservation of the intact VCR dimer, which suggests that metabolism involves alteration of side groups.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902455     DOI: 10.1002/cpt1977224430

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.

Authors:  M Scholz; C Engel; M Loeffler
Journal:  J Math Biol       Date:  2004-12-20       Impact factor: 2.259

3.  Vincristine potentiates cytochalasin B-induced DNA fragmentation in vitro.

Authors:  M A Kolber; P Hill
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Population pharmacokinetic model development and exposure-response analysis of vincristine in patients with malignant lymphoma.

Authors:  Toshiaki Igarashi; Shinji Kishi; Naoko Hosono; Takashi Higashi; Takahiro Iwao; Ryoichi Yano; Hitoshi Tsukamoto; Nobuyuki Goto; Takahiro Yamauchi; Takanori Ueda
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-08       Impact factor: 3.333

Review 5.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

6.  Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

Authors:  James W Behan; Vassilios I Avramis; Jason P Yun; Stan G Louie; Steven D Mittelman
Journal:  Pharmacol Res       Date:  2010-01-18       Impact factor: 7.658

7.  Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

Authors:  N H Greig; T T Soncrant; H U Shetty; S Momma; Q R Smith; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 8.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

9.  Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo.

Authors:  Darcy J P Bates; Lionel D Lewis; Alan Eastman; Alexey V Danilov
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

Review 10.  Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors.

Authors:  Hemant Sarin
Journal:  J Transl Med       Date:  2009-09-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.